A Study to Evaluate Maternal-fetal Immune Responses to Fetal Surgery


About this study

The purposes of this study are to determine whether maternal T cells are activated and expand after in utero intervention, and to determine whether placental macrophages and histology in the maternal-fetal interface exhibit increased activation and inflammation in surgical cases born preterm (<37 weeks) compared to term.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Surgery Cohort

  • Maternal age ≥ 18 years old.
  • Pregnant with a congenital anomaly diagnosis.
  • Undergoing endoscopic in utero fetal intervention.
  • Singleton pregnancy
  • Delivery planned at Mayo Clinic.

Control Cohort

  • Maternal age ≥ 18 years old.
  • Pregnant with normal ultrasound findings.
  • Singleton pregnancy
  • Delivery planned at Mayo Clinic.

Exclusion Criteria: 

  • Delivery planned elsewhere.
  • Abnormal fetal karyotype.
  • Multiples (i.e. twins/triplets, etc)
  • Undergoing open in utero fetal intervention

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mauro Schenone, M.D.

Open for enrollment

Contact information:

Maureen Lemens C.C.R.C.

(507) 293-1487


More information


Publications are currently not available